Alternate Day Buprenorphine Administration, Phase X - 15
Phase 2
Completed
- Conditions
- Opioid-Related Disorders
- Registration Number
- NCT00000233
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Opioid withdrawal Subjective dose estimate Drug effect characteristics: ARCI Money choice
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Treatment Research Center
🇺🇸Burlington, Vermont, United States